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We evaluated the feasibility, safety, and efﬁcacy of the administration of 4 sequential doses (intravenously
administered on days 1, 4, 11, and 18) of cryopreserved bone marrowederived mesenchymal stromal cells
(MSC) expanded with platelet lysate and obtained from third-party donors as a second-line treatment for
steroid-refractory acute graft-versus-host (aGVHD) disease in a series of 25 patients. All patients received at
least 2 doses of MSC, whereas 21 received 3 doses and 18 received the initially planned 4 doses. Because of
the achievement of partial response, 4 patients received additional doses of MSC. Median single cell dose
administered was 1.1  106 MSC/kg of recipient body weight. There were no adverse events related to the
MSC infusion in the 99 procedures performed, with the exception of a cardiac ischemic event that occurred
twice in a patient with prior history of cardiac ischemia. Response to MSC at 60 days after the ﬁrst dose was
evaluable in 24 patients. Seventeen patients (71%) responded (11 complete and 6 partial responses), with a
median time to response of 28 days after the ﬁrst MSC dose, whereas 7 patients did not respond. In summary,
we can conclude that sequential cryopreserved third-party MSC therapy administered on days 1, 4, 11, and 18
is a safe procedure for patients with steroid-refractory aGVHD. This strategy may provide a high rate of overall
responses of aGVHD with a low toxicity proﬁle.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD) remains the
main therapeutic challenge after allogeneic stem cell
transplantation (allo-SCT), especially for those patients who
are refractory to ﬁrst-line treatment based on steroids [1].
Although a number of immunosuppressive drugs have beenedgments on page 1584.
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14.06.015tested in this setting (including pentostatin, inﬂiximab,
antithymocyte globulin, and alemtuzumab, among others),
the ﬁnal outcome for steroid-resistant patients remains poor
[2]. Therefore, there is a clear need for new therapeutic
approaches, and 1 that has attracted great interest in the last
few years is mesenchymal stromal cell (MSC) therapy.
MSC are multipotent progenitors that can be isolated and
expanded from bone marrow (BM) and from other sources
[3]. They can differentiate into most cell types of the
hematopoietic niche, including osteoblasts, adipocytes, and
ﬁbroblasts [4]. In addition, MSC display immunomodulatory
properties in vitro, modulating the response of T cells, B cells,
or dendritic cells [5,6].
Because of these properties, MSC have been evaluated
in the treatment of several complications after allo-SCT,
including graft failure and graft-versus-host disease (GVHD).Transplantation.
Table 1
Patients’ Characteristics
Characteristics n (%)
Age
<40 yr 6 (24)
40-60 yr 8 (32)
>60 yr 11 (44)
Sex
Male 13 (52)
Female 12 (48)
Diagnosis
Acute myeloid leukemia 6 (24)
Myelodysplastic syndromes 7 (28)
Other diagnosis* 12 (48)
Disease status at transplantation
Complete remission 10 (40)
Partial response 5 (20)
Progression 10 (40)
Conditioning regimen
Myeloablative 6 (24)
Nonmyeloablative 19 (76)
GVHD prophylaxis
Tacro-rapa 10 (40)
Tacro-MTX 5 (20)
CsaþMTX 3 (12)
CsaþMTXþalentuzumab 2 (8)
CsaþMMF 3 (12)
Velcadeþrapa 1 (4)
TacroþMMF 1 (4)
GVHD, no. of organs involved
1 10 (40)
2 11 (44)
3 4 (16)
aGVHD
Skin
1-2 7 (28)
3-4 10 (40)
Gastrointestinal
1-2 10 (40)
3-4 10 (40)
Liver
1-2 3 (12)
3-4 4 (16)
Overall aGVHD grade
2 7 (28)
3 15 (60)
4 3 (12)
Tacro indicates tacrolimus; rapa, rapamycin; MTX, methotrexate; Csa,
cyclosporin; MMF, mofetil mycophenolate.
* Other diagnoses were Hodgkin (n ¼ 4) or Non-Hodgkin’s (n ¼ 3)
lymphoma, multiple myeloma (n ¼ 3), chronic lymphoid leukemia
(n ¼ 1), and acute lymphoblastic leukemia (n ¼ 1).
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evaluated the role of MSC for the treatment of refractory
aGVHD, showing that this approach is safe and potentially
effective, although there has not been a phase 3 randomized
clinical trials published to date [7]. Prior data from our group
showed that MSC from third-party donors is a feasible
approach and a number of patients needed more than 1 dose
to achieve response [8]. Therefore, we designed a phase 2 trial
with a main objective to evaluate the feasibility, safety,
and efﬁcacy of 4 sequential doses of third-party MSC cry-
opreserved for treating steroid-refractory aGVHD. Seventeen
patientswere included (2were not evaluable because they did
not receive MSC) in the trial EudraCT number: 2010-020947-
11 and, afterwards, we expanded this series with 10 additional
patients treated identically in our compassionate use program
with the same objectives as the trial.
DESIGN AND METHODS
MSC Production
All the procedures speciﬁed below were approved by the ethical com-
mittee of the Hospital Universitario de Salamanca and from each local
committee of the participating centers, and they were also in accordance
with the Helsinki Declaration of 1975, as revised in 2000. Informed consent
was obtained from all subjects and MSC donors included in the study. MSC
were isolated and expanded in the good manufacturing practice (GMP) cell
production facility of the Hospital Universitario de Salamanca (n ¼ 22), in
the GMP unit of the Clinica Universidad de Navarra (n ¼ 2), or in the GMP
unit of the Hospital Universitario Puerta de Hierro (n ¼ 1). A 100 mL BM
sample was obtained from each third-party healthy volunteer, following
standard procedures and with the same manufacturing process in all 3 cell
production units. MSC were expanded as previously described [8]. Brieﬂy,
mononuclear cells from BM were isolated by a density-gradient centrifu-
gation (Ficoll-Paque, GE Healthcare Bio-Sciences, AB, Uppsala, Sweden), and
cultured in noncoated polystyrene culture ﬂasks (Corning Costar, Celbio,
Milan, Italy) in modiﬁed Eagle’s medium-a with 1% penicillin/streptomycin
(Pen/Strep; Gibco, Paisley, UK) and supplemented with 5% of platelet lysate
(PL) at 37C in an atmosphere with 90% humidity and 5% CO2. The medium
was completely replaced twice a week. To obtain PL, 4 to 5 pooled platelets
from the blood bank were frozen at 80C and then thawed at 37C. The
platelets were used despite the ABO type and the volume of each pool was
300 to 400 mL. Samples were centrifuged at 900g for 30 minutes and the
supernatant was used as a supplement. To avoid gel formation, 10 interna-
tional units of heparin per 5 mL of medium was added before use.
Cells were characterized by ﬂow cytometry and differentiation assays, as
previously described [8], and karyotype analysis was performed following our
optimized method [9]. Brieﬂy, for immunophenotypic analysis, 200,000 cells
were incubated with the following antibodies: CD90-ﬂuorescein isothiocya-
nate (FITC), CD45-peridinin chlorophyll protein (PerCP), CD73-phycoerytrin
(PE) CD34-FITC, CD166-PE, CD19-PerCP, CD14-PE, HLA-DR PerCP.Cy5.5, all
from Becton-Dickinson BD (San Diego, CA), CD105-allophycocyanin from R&D
Systems (Minneapolis, MN), and CD44-FICT (from Immunostep, Salamanca,
Spain). A FACSCalibur cytometer (BD Biosciences) was used for sample
acquisition and data were analyzed using the Inﬁnicyt Software (Cytognos,
Salamanca, Spain). The multilineage differentiation studies to osteoblastic,
adipogenic, and chondrogenic lineages in vitro was performed using the
commercially available differentiation media from Miltenyi Biotec (Bergisch
Gladbach, Germany), following manufacturer’s instructions. Osteogenic dif-
ferentiation was conﬁrmed by alkaline phosphatase activity measured after
staining with NBT/BCIP solution (nitroblue tetrazolium chloride/5-bromo-4-
chloro-3-indolyl-phosphate) (Roche, Basel, Switzerland). Adipogenic differ-
entiation was conﬁrmed by Oil Red O staining (Certistain Merck KGaA,
Darmstadt, Germany), whereas chondrogenic stainingwas assessed by type II
collagen detection with a mouse antihuman type II collagen monoclonal
antibody (Chemicon International, Hofheim, Germany).
MSC were administered in ﬁrst passage in 12 patients (48%), in second
passage in 8 patients (32%), and in third passage in 5 patients (20%).
MSC Administration
MSC were administered intravenously immediately after being thawed.
Contents of the cryopreserved bag were transferred to a syringe for direct
administration over 10 minutes. Patients received 1 g i.v. of paracetamol and
10 mg of dexchlorpheniramine before MSC administration. Median single
cell dose administered was 1.1  106 MSC/kg of recipient’s body weight
(range, .7 to 1.31 106 MSC/kg). The same dose of MSC was repeated after 4,
11, and 18 days.Patient’s Characteristics
A total of 25 patients with steroid-refractory grades II to IV aGVHD were
included in the current study and treated using the same procedure.
Seventeen were enrolled in a phase 2 clinical trial (EudraCT number: 2010-
020947-11) in 5 different Spanish institutions from May 2011 to May 2012,
although 15 were evaluable (2 included patients did not ultimately receive
MSC), and the remaining 10 patients were treated by compassionate use in
the Hospital Universitario de Salamanca between May 2011 and April 2013.
Patients’ and transplantation characteristics are summarized in Table 1. In
the current study, the following criteria to deﬁne steroid refractoriness were
used: (1) progression of aGVHD after 3 days of therapy with 2 mg/kg of
methylprednisolone, (2) absence of any response after 7 days of therapy, or
(3) absence of partial response after 14 days of therapy.
Inclusion criteria for the clinical trial were grades II to IV aGVHD, re-
fractory to ﬁrst-line therapy with steroids, age between 20 and 65 years, and
normal cardiovascular and pulmonary function. Patients with disease pro-
gression at the time of inclusion or with uncontrolled bacterial, viral, or
fungal infection, or those with heart or pulmonary failure, were excluded.
For the compassionate use group, the same criteriawere considered, and the
reason for entering the compassionate use programwas either comorbidity
(n ¼ 2) or merely that the former trial was not started or already ended the
recruitment period (n ¼ 11). GVHD was graded according to the Seattle-
Glucksberg modiﬁed criteria [10].
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The response of the aGVHDwas evaluated according to standard criteria
[11] on aweekly basis until 60 days after the ﬁrst MSC dose. Brieﬂy, complete
response (CR) was deﬁned as absence of signs or symptoms of aGVHD, partial
response (PR) as a decrease of at least 1 grade from the day of the ﬁrst MSC
dose, and no response as no change in the GVHD grade. In case of progression
at day þ7, or absence of at least partial response at day þ21 or absence of
complete response at day þ28 after infusion, the patients were allowed to
receive additional MSC doses or a different treatment strategy or observa-
tion until day þ60, depending on the investigator’s criteria.
Patients on steroids were kept on the same dose until dayþ7 of theMSC
administration and then a 10% reduction every 5 days was performed in
those responding to MSC therapy. Progression after 7 days or absence of
response to MSC administration after 14 days of the ﬁrst dose was consid-
ered treatment failure and patients were subsequently removed from
the study.
An additional evaluation was performed for survival purposes after
12 months of the ﬁrst MSC dose.
Statistical Analysis
The SPSS (version 20.0; SPSS Inc, Chicago, IL) was used for statistical
analysis. Mean and median values, together with their corresponding 95%
conﬁdence intervals and ranges, were determined for each continuous
variable. To compare continuous and qualitative variables the student’s 2-
sample t-test and the Pearson’s chi-squared test were used, respectively. For
those comparisons where the use of parametric test was not appropriate,
the Mann-Whitney and the Fisher exact tests were employed. Overall sur-
vivalwas deﬁned as the time elapsed between the ﬁrst MSC dose and death
or last follow up, and it was calculated by the Kaplan-Meier method;
differences in survival were calculated using the log-rank test.
RESULTS
MSC Administration
The initial 4 intended doses of MSC were administered to
18 patients, whereas 3 received 3 doses and the remaining 4
patients received only 2 doses because of the absence of
response or because of toxicity in 1 case.
In our series, 6 patients achieved PR and were allowed to
receive additional therapy, based on the treating physician
decision. In this regard, 4 patients received additional doses
of MSC (2 patients received 3 additional doses and 2 patients
received 4 additional doses). The remaining patients received
Psoralen Ultra-Violet A (PUVA) and mofetil mycophenolate.
Median single cell dose administered was 1.1  106 MSC/
kg of recipient body weight, and median time from diagnosis
of refractory aGVHD to the ﬁrst MSC dose was 2.5 days
(range, 1 to 7 days).
There were no adverse events related to the MSC infusion
in the 99 procedures performed, with the exception of 1
patient who developed a cardiac ischemic event (angor
pectoris) 24 hours after the ﬁrst infusion. It is important to
note that the patient had prior history of ischemic disease
and had a stent, as well as cardiovascular risk factors (dia-
betes, hyperlipidemia), renal failure, and gastrointestinal
bleeding at that time. He was treated with red blood cell
transfusion and nitroglycerin infusion. After the second dose,
he develop a similar angor episode so MSC therapy was
discontinued.
GVHD Responses to MSC Therapy
Response to MSC therapy at 60 days after the ﬁrst dose of
MSC was evaluable in 24 patients. According to the estab-
lished response criteria, 17 patients (71%) responded to MSC
administration and 7 patients did not respond. Of the
responding patients, 11 achieved a CR and 6 achieved a PR.
Median time to response after the ﬁrst dose of MSC was
28 days (range, 9 to 58 days). Organ involvement is
summarized in Table 1. Complete responses by organ
(regardless of the number of organs involved in a particular
patient) were 81% for skin, 72% for gastrointestinal aGVHD,and 33% for liver. Responses to MSC therapy were similar in
all grades of GVHD, as CR rates were 50%, 43%, and 50% for
global grades II, III, IV, respectively.
For 2 of the 17 responding patients, aGVHD recurred
within 60 days after the ﬁrst MSC dose. Another 3 patients
suffered a GVHD ﬂare later on, after 72 days, 3 months, and
9 months of the MSC treatment, respectively. Two of them
had disease relapse and the GVHD ﬂared after discontinua-
tion of immunosuppressive drugs, and the remaining patient
developed grade I gastrointestinal GVHD, which responded
to topical treatment (beclomethasone dipropionate and
budesonide). The remaining 12 responding patients main-
tained their CR or PR after a median follow-up of 10.3 (range,
1.6 to 27.8) months. In all responding patients, steroids were
tapered until discontinuation. Five of the responding
patients died; causes of death are indicated in Table 2. Only 1
patient who achieved CR died of infection. This patient had a
septic shock by Escherichia coli and cytomegalovirus
reactivation (patient number 20 in Table 2).
In our analysis, we did not ﬁnd any relationship between
response to MSC therapy and a number of clinical or labo-
ratory parameters, including age, sex, Eastern Cooperative
Oncology Group status, conditioning regimen, underlying
disease, disease status at transplantation, GVHD prophylaxis,
and absolute lymphocyte counts. Results of these compari-
sons are summarized in Table 3.
After 12 months of the ﬁrst MSC dose, 5 patients in the
nonresponding group (71%) had died; 4 because of GVHD
and 1 because of infection. In the MSC-responding group, 9
patients died (52%); 4 because of GVHD, 3 because of
infections, and the remaining 2 patients because of disease
progression. Interestingly, 8 of the 11 patients who achieved
CR were alive at the last follow-up, whereas only 3 of the 14
patients who achieved PR or no response were alive. These
patients received alternative treatments for GVHD. Patients
number 16 and number 23 (see Table 2) received rapamycin
and steroids. Patient number 24 received rapamycin and
extracorporeal photoapheresis.
Finally, we evaluated the incidence of infectious diseases
within the 60 days after the ﬁrst MSC dose. We found de
novo CMV reactivation in 10 patients (40%), invasive asper-
gillosis in 3 patients (12%), and bacterial infections in 8
patients (32%).
DISCUSSION
In the current study, we report the result of a series of 25
patients with refractory aGVHD uniformly treated with
third-party human BM-derived MSC expanded with PL
administered in a sequential basis on days 1, 4, 11, and 18.
This administration schedule was planned in an attempt to
increase the rate of maintained responses. There are a
number of differences between our study and some previous
reports on the use of MSC in the aGVHD setting.
First, inmost of the previously reported studies (including
our own data) [8,12] cells have been expanded with either
fetal calf serum or human autologous serum. We previously
demonstrated that the immunophenotype, the multilineage
differentiation ability, and the immunomodulatory proper-
ties of MSC are similar when expanded with FSC, autologous
serum, and PL [13]. The use of PL avoids the need of animal
supplements for MSC expansion, a strategy with obvious
advantages. The use of autologous serum also avoids the use
of animal-derived products but implies performing a
plasmapheresis to the donor to obtain enough serum for the
whole process of expansion and greater variability. Data from
Table 2
Outcome after MSC Therapy
Patient No. aGVHD Grade Response to MSC within 60 d after First Dose Status at 12 Mo. Cause of Death
Organ Involvement Global
1 Gut II III PR Dead Infection
2 Skin I, gut III III CR Alive
3 Gut II III NR Dead GVHD
4 Gut II III CR Alive
5 Skin III, gut II, liver IV IV CR Dead GVHD
6 Skin IV, gut I IV NR Dead GVHD
7 Skin III, gut I, liver II III CR Alive
8 Gut III, liver III III PR Dead GVHD
9 Skin II, gut III, liver III III CR Alive
10 Skin II, liver I II Not evaluable Dead Infection
11 Skin III, gut III III PR Dead GVHD
12 Skin I, gut III III NR Dead GVHD
13 Gut III, liver III III CR Alive
14 Gut III III PR Dead GVHD
15 Skin II II CR Alive
16 Skin III II NR Alive
17 Gut IV IV PR Dead Relapse
18 Skin IV, gut II IV CR Dead Relapse
19 Skin III II CR Alive
20 Skin I, gut III III CR Dead Infection
21 Skin III, gut I, liver III III NR Dead GVHD
22 Skin III II PR Dead Infection
23 Gut III III NR Alive
24 Skin II, gut I II NR Alive
25 Skin III, gut I II CR Alive
NR indicates no response.
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optimal for MSC in some cases, and PL has to be added to
obtain the targetMSC dose [8,14]. Therefore, this complicates
the process, is disturbing for the donor, and increases theTable 3
Parameters That Did Not Inﬂuence Response to MSC
Factor Response
to MSC, %
No Response
to MSC, %
P Value
Age .20
<40 yr 67 33
40-60 yr 50 50
>60 yr 90 10
Sex .20
Male 62 38
Female 83 17
Conditioning regimen .60
Myeloablative 83 17
Nonmyeloablative 68 32
Disease status at
transplantation
.60
Complete remission 63 37
Partial response 80 20
Progression 67 33
Second complete remission 100 0
GVHD prophylaxis .30
Tacro-rapa 80 20
Tacro-MTX 40 60
CsaþMTX 33 67
CsaþMTX
þalentuzumab
100 0
CsaþMMF 100 0
Velcadeþrapa 100 0
TacroþMMF 100 0
ECOG .30
0-2 70 30
>2 67 33
Absolute lymphocyte counts .50
Low 70 70
Normal 67 30
ECOG indicates Eastern Cooperative Oncology Group performance status.costs. The use of PL overcomes these issues and a number of
groups have incorporated it into the GMP MSC production
process [15,16], although few reports have been published on
the use of PL-expanded MSC for GVHD therapy [17,18].
The ﬁrst reports on the use of MSC in steroid-refractory
aGVHD demonstrated that MSC were safe and effective, but
in most studies, patients received only 1 or 2 doses of MSC
[12,19,20]. In a recent manuscript from Ball et al., inwhich the
authors retrospectively analyze their results in a series of 37
children with steroid-refractory aGVHD [21], the authors
showed that multiple doses of MSC were associated with a
higher rate of CR. In their series, the median number of doses
was 2, but 12 of 37 children received between 3 and 5 doses,
and the rate of CR was 65%. In that study, there were no
complications related to MSC administration. In a recent
manuscript describing the Israeli experience of 50 patients
treated with BM-MSC for refractory aGVHD, a number of pa-
tients also received more than 1 dose, but not in a scheduled
mode. In this series, an heterogeneous population of adults
and pediatric patients were treated with MSC from either the
same donor as for hematopoietic stem cell transplantation,
haplo, or third-party MSC donors, and patients were receiving
several other concomitant immunosuppressive drugs [22].
We did not observe any adverse event related to the
infusion of MSC in 99 procedures with the exception of an
ischemic event that occurred twice in 1 patient with high
cardiovascular risk (see results section). Nevertheless, it is
important to note that MSC should be administered with
caution or should be avoided in hemodynamically unstable
patients with high cardiovascular risk.
Regarding responses, in the current study we describe a
high rate of overall responses (71%), with a CR rate of 42%.
The overall response rate is almost 10% higher than reported
by the European MSC Consortium, although this series
included patients treated with MSC in third and subsequent
lines, and for this reason a lower response rate would be
expected in their results [12], as it has been described in
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comparative studies have been carried out to assess the
efﬁcacy and safety of second-line therapy for aGVHD. Hence,
clinicians must rely on reports of retrospective studies and
single-arm phase 2 studies to evaluate the merits of any
given treatment. With these limitations in mind, the overall
and CR rate observed in the current series are in the range of
the best results previously reported using other approaches
[23]. Regarding responses by organ, in the current study,
responses to MSC are higher for skin and GI (over 70%) as
comparedwith liver, where only 33% responsewas observed.
This is in agreement with other reports [17], but this issue
requires further studies to gain insight in the biological
mechanisms responsible for this organ-related response
pattern.
It should be stressed that the current data support
previous studies suggesting that MSC treatment is not
associated with a high incidence of infectious complications
[24]. In fact, the incidence of cytomegalovirus reactivation,
invasive aspergillosis, or bacterial infections reported in our
study is lower compared with other strategies used in this
setting [25-28]. In this regard, the use of antithymocyte
globulin is associated with high mortality, in spite of a high
response rate, as reported by Arai et al., which described
survival in 4 of 69 steroid-refractory patients [29]. Results
with other new drugs, such as anti-CD3 or anti-CD25 anti-
bodies, have resulted in overall survival in the range of 30% to
50% with high rates of infections [30-32]. Inﬂiximab, an anti-
TNF alpha molecule, is associated with response rates in the
range of 50% to 60% but also with a high mortality rate
because of infectious complications [33,34]. It can be
hypothesized that 1 of the reasons for the lower rate of in-
fections is the absence of hematological toxicity after MSC
therapy, which is also being explored to treat cytopenias
after allo-SCT [35]. The ultimate consequence of the low
toxicity is that those patients achieving a CR after MSC
therapy have a high rate of survival, in our series, as shown in
Figure 1. Nevertheless, the short period of observation of our
study has to be taken into consideration as 1 of its major
limitations.
There are no compelling data that allow predicting which
patients would beneﬁt most fromMSC therapy. Some groups
have suggested that those patients who start the MSC earlierFigure 1. Inﬂuence on overall survival of achieving CR after MSC therapy for
aGVHD.might have a better response rate [21,22], and other authors
have found an association between response rate and a
higher baseline lymphocyte counts or a decrease in bio-
markers, such as Reg 3 alpha or elaﬁn [36]. Finally, several
groups have shown better results in children compared with
in adults [12,22], and time from hematopoietic stem cell
transplantation to MSC therapy might inﬂuence the efﬁcacy
of the procedure [22]. In our work, including patients ho-
mogeneously treated with MSCs as second-line treatment,
we did not ﬁnd any inﬂuence of the lymphocyte counts or
any other clinical parameter analyzed, including age, sex,
Eastern Cooperative Oncology Group status, GVHD prophy-
laxis, type of conditioning regimen, or disease status at
transplantation on the response rate (see Table 3). This can
be because of the low number of patients or because of the
fact that many of these parameters were very homogeneous
in our series of patients.
In summary, we can conclude that sequential cry-
opreserved third-party MSC therapy administered on days 1,
4, 11, and 18 is a safe procedure for patients with steroid-
refractory aGVHD. This strategy may provide a high rate of
overall responses of aGVHD, close to 70%, with low toxicity.
Phase 3 randomized trials should be performed to assess the
role of sequential MSC therapy in this setting.ACKNOWLEDGMENTS
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